MARLBOROUGH, Mass.--(BUSINESS WIRE)--Acton Pharmaceuticals, Inc., a specialty respiratory pharmaceutical company, today announced that positive results from a Phase IIIB clinical trial of AEROSPAN were published this month in Annals of Allergy, Asthma & Immunology in a manuscript titled, “Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: A randomized, double blind, placebo-controlled trial.” The abstract is available online at http://www.annallergy.org/article/S1081-1206(11)00563-1/abstract.
